BioSpace· Tristan Manalac·· 5 hours agoPickScore66
Lilly puts $1.1B on the line for Hong Kong biotech’s AI drug delivery platform
In brief
Eli Lilly has partnered with Hong Kong-listed METiS TechBio to develop lipid nanoparticle delivery technology using its AiLNP platform. Lilly will pay an upfront of "low double-digit millions of U.S. dollars," plus up to $1.1 billion in development, regulatory and commercialization milestone payments, along with single-digit tiered royalties on sales.
Why it matters
The article discloses the upfront and milestone structure, showing how Lilly expands its delivery technology portfolio through an AI lipid nanoparticle platform.
Source: BioSpace